Tyrosine-protein kinase Tec
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Tec as ChEMBL target CHEMBL4246, mapped to UniProt P42680. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Tyrosine-protein kinase Tec matters
Tyrosine-protein kinase Tec is reviewed as Tyrosine-protein kinase Tec (UniProt P42680); the current evidence base includes 15 approved drugs, 1366 compounds, and 297 assays, with lead potency reaching pChEMBL 10.1.
Tyrosine-protein kinase Tec Sequence length is 631 aa.
Review this target as Tyrosine-protein kinase Tec, mapped to UniProt P42680. Sequence length is 631 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 15 approved drugs, 1366 compounds, and 297 assays for this target. The dominant activity type is KD. CHEMBL5827965 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL5827965 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Tyrosine-protein kinase Tec matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P42680, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5827965
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL4206765
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL4217959
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL4214683
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5780981
|
9.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
RITLECITINIB
CHEMBL4085457
|
2023 |
|
|
TIRABRUTINIB
CHEMBL4071161
|
2020 |
|
|
ZANUBRUTINIB
CHEMBL3936761
|
2019 |
|
|
ACALABRUTINIB
CHEMBL3707348
|
2017 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |